글로벌 바이러스성 간염 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

WHO가 2021년 7월에 발표한 자료에 따르면, 2019년까지 전 세계적으로 2억 9,600만 명이 만성 B형 간염 바이러스에 감염되어 살고 있으며, 매년 150만 건의 새로운 감염이 발생합니다. B형 간염 감염률이 가장 높은 지역은 서태평양과 아프리카의 WHO 지역으로, 각각 6.2%와 6.1%의 사람들이 감염됩니다. 간의 염증을 간염이라고 합니다. 염증은 신체가 자극이나 부상에 반응하는 것이며, 일반적으로 붓기와 통증을 유발합니다.

Data Bridge Market Research는 바이러스성 간염 시장이 2021년에 149억 8천만 달러 규모였으며 2029년까지 197억 3천만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 3.50%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크도 포함되어 있습니다.

보고 범위 및 시장 세분화

Market Definition

Viral hepatitis is a long-term or severe infection that causes liver enlargement and inflammation. Contaminated food and water are the sources of the disease. It is contagious and spreads by close contact with bodily fluids such sweat, stool and blood. Antiviral drugs are a type of medicine that is used to treat viral illnesses like HIV, herpes, hepatitis, and influenza. Vaccines are the most common form of administration for these medications. Furthermore, the majority of these medications are used to treat specific viral infections, but a select handful (broad-spectrum antiviral treatments) are effective against different virus forms. Antiviral medications used to treat viral infections of the liver, such as hepatitis, are known as hepatic antiviral agents.

Viral Hepatitis Market Dynamics

Drivers

• Rise in the prevalence of hepatitis

The rising prevalence of hepatitis is a major factor driving the viral hepatitis market's growth rate. According to World Health Organization (WHO) data published in July 2021, an estimated 58 million individuals have chronic hepatitis C virus infection, with 1.5 million new infections occurring each year. The hepatitis C virus is a blood-borne pathogen, and the most common way to contract it is by contact with small amounts of blood. This frequently occurs as a result of improper injections and poor health care. 

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of viral hepatitis market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness about the will expand the viral hepatitis market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of viral hepatitis market. Along with this, rising geriatric population and surge in medical tourism will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the viral hepatitis market growth. In March 2021, Dicerna Pharmaceuticals and Roche began a Phase II combo trial for the treatment of chronic hepatitis B virus (HBV) infection with the experimental GalXC RNAi candidate, RG6346. As a result, market research and development activities are crucial to improve market expansion.

• Launch of new products

The launch of new products is estimated to boost the new market opportunities. Mavyret (glecaprevir and pibrentasvir) pills, for instance, were approved by the US Food and Drug Administration in April 2019 to treat six genotypes of hepatitis C virus (HCV) in children aged 12 to 17. Furthermore, in June 2021, Gilead Sciences, Inc. got FDA approval for Epclusa for the treatment of chronic hepatitis C virus (HCV) in children under the age of three, regardless of HCV genotype or severity of liver disease.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the viral hepatitis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost of the treatment will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and low awareness about viral hepatitis will pose major challenges to the market's growth rate. Additionally, the dearth of skilled professionals and strict government regulations will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This viral hepatitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the viral hepatitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Viral hepatitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Viral Hepatitis Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, and inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of viral hepatitis in recent months.

Recent Development

• In May 2022, Abbott announced the launch of HBsAg Next Assay in India for early detection of Hepatitis B. The HBsAg Next Qualitative Assay identifies HBV surface antigen (HBsAg) in human serum and plasma, making it a sophisticated, next-generation assay for earlier detection of HBV. It also overcomes typical obstacles by demonstrating the greatest level of assay performance needed to detect infection in immunocompromised individuals.

Global Viral Hepatitis Market Scope

The viral hepatitis market is segmented on the basis of disease type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Hepatitis A
• Hepatitis B
• Hepatitis C
• Others

Treatment

• Antiviral Drugs
• Telbivudine
• Entecavir
• Tenofovir disoproxil
• Lamivudine
• Others
• Vaccine
• Immune Modulator Drugs
• Pegylated interferon
• Interferon alpha
• Surgery
• Others

Diagnosis

• Liver Biopsy
• Blood Tests
• Imaging Tests
• Ultrasound
• MRI
• CT scan
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Viral Hepatitis Market Regional Analysis/Insights

The viral hepatitis market is analysed and market size insights and trends are provided by country, disease type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the viral hepatitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

북미는 주요 핵심 기업의 존재감 증가와 증가하는 수의 연구 및 개발 활동으로 인해 바이러스성 간염 시장을 지배하고 있으며, 이는 이 지역의 시장 성장률을 더욱 촉진할 것입니다. 또한 FDA 승인 약물의 수가 증가함에 따라 이 지역의 시장 성장률이 더욱 촉진될 것입니다. 

아시아 태평양 지역은 제네릭 제조업체의 급증과 이 지역의 정부 이니셔티브 확대로 인해 예측 기간 동안 성장할 것으로 예상됩니다. 또한, 의료 인프라의 개발은 이 지역의 시장 성장률을 더욱 촉진할 것입니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 바이러스성 간염 시장 점유율 분석

바이러스성 간염 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 바이러스성 간염 시장과 관련된 회사의 초점에만 관련이 있습니다.

바이러스성 간염 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 사노피(프랑스)
• 베링거 인겔하임 인터내셔널 GmbH. (독일)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• Bayer AG(독일)
• 머크앤코(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 카딜라 파마슈티컬스(인도) 
• 엘리 릴리 앤드 컴퍼니(미국)
• LEO Pharma A/S(덴마크)
• 시플라 주식회사(미국)
• Aurobindo Pharma(인도)
• 루팡(인도)
• 스미토모 주식회사(일본)

SKU-53352